S troke is a major healthcare problem attributable to ≈10% of deaths worldwide. 1 In industrialized countries, stroke is the third most common cause of death, and the leading cause of disability, with 20% of survivors requiring institutional care after 3 months and 15% to 30% being permanently disabled.
Adding a second antiplatelet agent to aspirin could be a potential strategy for primary prevention of stroke in patients at high risk for stroke or for secondary prevention after a first cerebrovascular event. To date, the effect of adding clopidogrel or 1 of the novel ADP receptor inhibitors to aspirin in preventing ischemic stroke, or causing intracranial hemorrhages, has not been systematically reviewed. Therefore, we performed a systematic review and a meta-analysis to investigate the efficacy (prevention of stroke) and safety (intracranial hemorrhage) of ADP receptor inhibitors as compared with aspirin in patients at high risk for cardiovascular disease (overall cohort) and in patients with previous TIA or stroke (secondary prevention cohort).
Methods
The review protocol has been written and reported in advance according to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement 18 and registered on a PROSPERO Website (CRD42011001596).
Inclusion Criteria
To meet the inclusion criteria, selected studies had to be randomized controlled trials (RCTs) with ≥1 cerebrovascular outcome comparing aspirin 75 to 100 mg with ADP receptor inhibitors (other than ticlopidine).
Population

Overall Population
The overall population consisted of patients with cardiovascular disease with and without any previous cerebrovascular events across all studies.
Secondary Prevention Cohort
In the secondary prevention group, all studies were included where participants received antiplatelet therapy because of previous ischemic cerebrovascular disease (previous TIA or stroke).
Search Strategy
We searched the Cochrane Central Register of Controlled Trials (CENTRAL; date of inception to 3rd quarter 2011), MEDLINE (date of inception to September 20, 2011) , and Web of Science (date of inception to present). We checked the references of retrieved studies for additional trials. We used no language restrictions. Suspected relevant citations were screened at the title and abstract level and retrieved, if potentially pertinent, as full reports. Eligible reports were assessed for methodological quality.
Intervention
We searched for the following interventions: (1) aspirin monotherapy compared with clopidogrel monotherapy, (2) clopidogrel monotherapy compared with a combination of aspirin and clopidogrel, (3) aspirin monotherapy compared with a combination of aspirin and clopidogrel, and (4) a combination of aspirin and clopidogrel compared with a combination of aspirin and a novel ADP receptor inhibitor (prasugrel or ticagrelor). The primary outcome parameter was the total stroke rate (any cerebrovascular event consisting of TIA, fatal or nonfatal stroke, or intracranial hemorrhage). Secondary outcome parameters were ischemic stroke or TIA and intracranial hemorrhage. The search terms are listed in the Methods section in the online-only Data Supplement. A standard RCT filter was used for the MEDLINE search.
Two reviewers independently and in duplicate applied the selection criteria (G.G. and J.M.S.-M.). Studies were rejected if one could determine from the title or abstract, or both, that the study was not suitable for inclusion into this review. Full text of the study was obtained and carefully evaluated if an article could not be excluded with certainty. Excluded studies were compared and any disagreement was resolved through discussion between the reviewers.
Quantitative Statistical Analysis
Attrition bias referring to systematic differences between the comparison groups due to loss of participants from the study was addressed carefully by reviewing the reporting of withdrawals, dropouts, protocol deviations, and losses to follow-up. To avoid selection bias, we did not reject any study because of methodological characteristics or any subjective quality criteria. Differences in study methods were examined in sensitivity analyses.
Variables are reported as number or percentage as appropriate. Risk ratios (RRs) were computed from individual studies and pooled according to the inverse model with 95% confidence intervals (CIs) using RevMan version 5.0 (Cochrane Collaboration) as appropriate. We assessed studies for clinical and statistical heterogeneity. To assess statistical heterogeneity we calculated the I 2 index and a P value. Values of ≈25% (I 2 =25), 50% (I 2 =50), and 75% (I 2 =75) indicate low, medium, and high heterogeneity, respectively.
19 Fixed-effect model was used for I 2 <50%, whereas random-effect model for I 2 >50%. We also compared the estimates calculated by both models in a separate analysis.
We performed a sensitivity analysis to determine the robustness of effect estimates against within-study bias risk. Sensitivity analyses were conducted by excluding sequentially one study and adding subgroups: (1) studies with a short versus long follow-up (≥4 weeks versus <4 weeks), (2) ischemic stroke versus intracranial hemorrhage, (3) sample size (n≥4000 versus n<4000), and (4) type of coronary artery disease (stable versus acute coronary syndrome). Six variables were included for assessment of bias risk: adequate sequence generation, allocation concealment, blinding to treatment arm, blinded treatment assessment, intention-to-treat analysis, and incomplete outcome data assessment. Trials without blinded outcome assessment or blinding to treatment arm were assumed as studies with high bias risk. In addition, numbers needed to treat were computed using the inverse of underlying risk as indicated by the control event rate. Small study bias or reporting bias was appraised by graphic inspection of funnel plots. Unadjusted P values are reported throughout, with hypothesis testing set at the 2-tailed significance level of 0.05. Variables are reported as number or percentage as appropriate.
Results
Description of Studies
Our search exhibited 715 references. We excluded 629 references based on title and abstracts that were not RCTs, were duplicates, or investigated different topics. We excluded 15 additional references because of a noneligible intervention or a noneligible population. We retrieved the remaining 72 full-text articles for inspection. Six additional papers were included in the revised manuscript [20] [21] [22] [23] [24] [25] (at time of first submission, data were not published online). Of these, 22 studies consisting of 173 371 patients met our inclusion criteria (Figure 1 ). Patients
Stroke
February 2014
included in our meta-analysis comparing dual antiplatelet therapy (DAPT) versus antiplatelet monotherapy were subjects with established cardiovascular disease such as coronary artery disease (67%), heart failure (10%, of which 70% with ischemic cardiomyopathy), atrial fibrillation (4%), and previous stroke or TIA (21%; see Table) . Definitions of clinical events or outcomes are listed in Table I in the online-only Data Supplement. We excluded 5 randomized trials consisting of 2 studies with atopaxar, 38,39 2 studies with cangrelor, 40, 41 and 1 study with terutroban 42 because of high heterogeneity in drug regimen, treatment period, and the fact that the agents are currently not approved by international authorities.
Monotherapy With Clopidogrel Versus Aspirin
Overall Population Two randomized trials, 11, 26 comprising a total of 20 232 patients, were pooled to calculate the efficacy of clopidogrel monotherapy as compared with aspirin monotherapy during a median follow-up of 22 months. Overall, 5.5% (556 of 10 123) of patients experienced a stroke (total stroke) in the clopidogrel group compared with 6.0% (608 of 10 109) in the aspirin group. Clopidogrel monotherapy, therefore, did not reduce the total stroke risk as compared with aspirin alone (RR, 0.91; 95% CI, 0.82-1.02; P=0.11; I 2 =0%; Figure 2A ). Figure 2C ).
Secondary Prevention Cohort
Only data of CAPRIE trial were available for the secondary prevention analysis. 11 During a median follow-up of 22.9 months, 9.6% (315 of 3233) of patients experienced a total stroke in the clopidogrel group compared with 10.5% (338 of 3198) of patients in the aspirin group. Although a trend was observed, clopidogrel was not superior to aspirin for secondary prevention of total stroke in the CAPRIE trial (RR, 0.92; 95% CI, 0.80-1.07; P=0.27; Figure 2D ).
DAPT With Clopidogrel and Aspirin Versus a Monotherapy With Aspirin
Overall Population Ten RCTs reporting on the impact of DAPT with aspirin and clopidogrel versus aspirin alone consisting of 93 405 patients were pooled. 20, 23, 24, 27, [29] [30] [31] [32] [33] 36 In this analysis, Figure 3C ). The estimated number of patients needed to treat with clopidogrel and aspirin, as compared to aspirin alone in order to prevent one ischemic stroke or TIA, would be 231 (95% CI=167 to 374). The estimated number of patients needed to harm with clopidogrel and aspirin with respect to one additional major intracranial bleeding event would be 7606 (95% CI= -infinity to -1218 and 1793 to +infinity). 
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Secondary Prevention
Data from 7 trials comparing DAPT with aspirin and clopidogrel versus aspirin alone consisting of 13 237 patients reported on the incidence of a second cerebrovascular event in patients who already had a history of TIA or stroke. 21, 25, 28, 29, 32, 34, 36 During a median follow-up period of 12 months, 7.0% (464 of 6621) of patients in DAPT with clopidogrel and aspirin and 9.2% (607 of 6616) of patients in monotherapy with aspirin experienced a recurrent stroke, thus demonstrating a 24% RRR in the total stroke rate (ischemic stroke, TIA, or intracranial hemorrhage; RR, 0.76; 95% CI, 0.68-0.86; P<0.0001; I 2 =0%; Figure 3D ). The MATCH (aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients) trial comparing clopidogrel and aspirin versus clopidogrel alone did not show any benefit in regard to the reduction of overall stroke for secondary prevention 35 (RR, 0.98; 95% CI, 0.85-1.13; P=0.76; Figure 3D ).
Sensitivity Analyses
Sensitivity analysis assessing the duration of follow-up showed that the direction of effect of use of DAPT with clopidogrel and aspirin on stroke in the overall cohort and in secondary prevention remained unchanged. However, the magnitude of the effect tended to be greater in studies with a long-term follow-up (>4 weeks; RRR in the overall cohort, 22%) versus short-term follow-up (≤4 weeks; RRR in the overall cohort, 17%). Sensitivity analysis assessing the sample size showed that the direction of effect of DAPT with clopidogrel and aspirin on stroke in the overall cohort remained unchanged. However, the magnitude of effect tended to be greater in studies with smaller sample size (n<4000; RRR, 27%) versus studies with larger sample size (n>4000; RRR, 20%).
Sensitivity analysis assessing the type of coronary artery disease (stable versus acute coronary syndrome) indicated that DAPT with clopidogrel and aspirin reduced the relative risk of overall stroke in patients with acute coronary syndrome by 16% (RR, 0.84; 95% CI, 0.73-0.970; P<0.0001) and in patients with stable coronary artery disease by 13%, which did not reach statistical significance (RR, 0.87; 95% CI, 0.73-1.05; P=NS).
By sequentially excluding 1 single study from the analysis, it was shown that the direction of effect and the magnitude of effect of use of DAPT with clopidogrel and aspirin on stroke remained unchanged. Figure 4C ) in the overall study population. However, there was a trend toward higher risk of intracranial hemorrhage in the ticagrelor group (RR, 1.76; 95% CI, 0.89-3.47; P=0.1; Figure 4C ).
DAPT With Aspirin and
Secondary Prevention
Data from subgroups of 2 trials comparing DAPT with aspirin and prasugrel or ticagrelor versus aspirin alone, consisting of 1670 patients, reported on the incidence of a second cerebrovascular event in patients who already had a history of TIA or stroke. 43 Figure 4D ). Significant heterogeneity of the analysis was observed (I 2 =86%). Although prasugrel resulted in a 10.3-fold higher relative risk of overall stroke in secondary prevention (RR, 10.26; 95% CI, 2.43-43.41; P<0.002; Figure 4D ), ticagrelor was not associated with a higher risk (RR, 1.22; 95% CI, 0.66-2.26; P=0.54; Figure 4D ).
Reporting Bias/Small Study Effects
Visual inspection of funnel plots indicated a minor asymmetry. Therefore, reporting bias and small study effects cannot be excluded (funnel plots not shown).
Random-Versus Fixed-Effect Estimates
Based on the clinical heterogeneity of the included studies, we undertook a comparison of the results revealed by a randomand fixed-effect model, which showed no significant differences (Table II in 
Discussion
The main finding of this systematic review and meta-analysis of RCTs is that combination of low-dose aspirin plus clopidogrel versus aspirin monotherapy reduced the relative risk of total stroke by 20% and the risk of ischemic stroke by 23% in the overall population consisting of patients with cardiovascular disease with and without previous cerebrovascular event during a median follow-up period of 12 months. Concordantly, a 24% RRR for a recurrent stroke was calculated for the secondary prevention cohort during a median follow-up period of 12 months. Importantly, the risk of intracranial hemorrhage by use of DAPT with clopidogrel and aspirin was not increased. Our meta-analysis suggests that DAPT combining low-dose aspirin (75-100 mg) and clopidogrel (75 mg) should be further investigated as a strategy to reduce recurrent strokes.
Although clopidogrel was marginally superior to aspirin in the CAPRIE trial 11 (8.7% reduction in the relative risk for the composite end point of ischemic events), no difference was seen in the subset of patients with previous ischemic 
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February 2014 stroke (RR, 7.3%; 95% CI, 5.7-18.7). Despite the fact that in the CAPRIE trial 11 superiority of clopidogrel compared with aspirin for stroke prevention was observed neither in the overall cohort nor in the secondary prevention cohort, current guidelines support the use of clopidogrel monotherapy for secondary stroke prevention. 5 Interestingly, there was a trend toward lower risk of intracranial hemorrhage by use of clopidogrel as compared with aspirin, which might be a potentially important safety advantage and should be explored in larger studies. In contrast, the guidelines do not support the use of combination of aspirin and clopidogrel (grade III) for secondary prevention because of the increased risk of bleeding 5 shown in the MATCH trial. 35 In the MATCH trial, clopidogrel (75 mg) was compared with DAPT combining aspirin (75 mg) and clopidogrel (75 mg) in high-risk patients with recent ischemic stroke or TIA and with ≥1 additional vascular risk factor and who were already treated with clopidogrel.
The results of our meta-analysis did not confirm previous assumptions: combination of aspirin plus clopidogrel versus monotherapy with aspirin or clopidogrel reduces the relative risk of total stroke (ischemic stroke, TIA, or intracranial hemorrhage) by 24% in secondary stroke prevention and of ischemic stroke by 23% in the overall population. Intracranial hemorrhage was chosen as the most disabling and potentially lethal bleeding complication, which was not higher in studies included in our meta-analysis. In line with our findings, recent publication of a RCT showed that the balance of antiplatelet therapy lies in favor of dual rather than single antiplatelet therapy. 25 Our analysis confirms the findings of 2 other meta-analyses 45, 46 : DAPT significantly reduced vascular outcomes. In line with the latter, there is increasing evidence that a short course of a more intensive antiplatelet regimen might be effective in the acute phase after TIA or minor stroke. 47 The superiority of DAPT with clopidogrel and aspirin compared with antiplatelet monotherapy within the first 3 days after the acute stroke was confirmed in a recently published meta-analysis. 46 Furthermore, the results of our meta-analysis are in line with a meta-analysis investigating the effects of combined therapy with aspirin and clopidogrel on the composite of cardiovascular outcomes. Overall, the addition of aspirin to clopidogrel, as compared with a single-drug therapy, resulted in a 9% RRR in major cardiovascular events and 14% RRR in myocardial infarction. 48 Interestingly, based on our analysis, the rate of stroke in patients with cardiovascular diseases was even higher than that of patients with stent thrombosis as reported recently (5% versus 2%), 13, 14 which further underlines the importance of stroke prevention with DAPT.
Current American Heart Association (AHA) guidelines recommend the combination of aspirin and dipyridamole (Class I; Level of Evidence B) or clopidogrel monotherapy (Class IIa; Level of Evidence B) but not the combination of aspirin and clopidogrel (Class III) for secondary stroke prevention. 5, 7 It is to be noted that in our meta-analysis, clopidogrel plus aspirin compared with aspirin reduced recurrent total stroke by 24% (13 237) in patients with previous ischemic stroke, which is similar to the RRR by use of dipyridamole plus aspirin compared with aspirin alone, according to a published meta-analysis (RRR, 23%; 7648 patients). 49 Because the magnitude of effect size of the latter strategies is in the same range, one could extrapolate that both antiplatelet combinations might be safely used for secondary stroke prevention. Nevertheless, because no direct comparison between clopidogrel plus aspirin versus dipyridamole plus aspirin is available, this indirect comparison of RRR between different antiplatelet strategies should be considered as only hypothesis-generating. Of note, the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) 50 trial found that clopidogrel alone caused less intracranial hemorrhage compared with dipyridamole plus aspirin in a cohort of patients with previous ischemic stroke. Similarly, the MATCH trial 35 revealed that DAPT caused slightly more intracranial bleeding compared with clopidogrel monotherapy. As expected, the rate of intracranial hemorrhage was also increased by adding a more potent platelet inhibitor, varopaxar, to DAPT. 51 It is reasonable to assume that bleeding risk increases with the number of antiplatelet agents. In this case, the net clinical benefit (a composite of ischemic and bleeding events) might be considered the end point of special interest. However, our meta-analysis indicates that DAPT, compared with aspirin, improved the net clinical end point for secondary stroke prevention, with no difference in the event rates for DAPT versus clopidogrel (based on the results of MATCH). Therefore, the fundamental question whether to recommend dual antiplatelet therapy for secondary stroke prevention seems to be still unanswered.
Several other antiplatelet regimens such as ticlopidine and cilostazol have been identified as potential candidates for stroke prevention. Ticlopidine is, however, not recommended anymore for routine clinical use because of safety concerns, including side effects such as blood and immune disorders. 5, 52 Cilostazol, a phosphodiesterase inhibitor, was compared with aspirin for secondary stroke prevention in 2 randomized trials. In a meta-analysis comprising these 2 trials with 3477 patients, cilostazol was not associated with a lower relative risk of ischemic stroke (RR, 0.80; 95% CI, 0.61-1.07) but lowered the risk of hemorrhagic stroke by 74% as compared with aspirin. 53 We also included the Secondary Prevention of Small Subcortical Strokes (SP3) study into the meta-analysis. 21 The SP3 trial was prematurely withdrawn because of an increased risk of overall bleeding and mortality with combination therapy of clopidogrel and aspirin in patients with subcortical (lacunar) stroke. One must note, however, that only ≈25% of ischemic strokes are lacunar in type. 54 The small lesions are localized predominantly in the white matter and the deep grey matter, both supplied by the lenticulo-striatal arterioles. 55 Most lacunar strokes result from intrinsic disease of those small penetrating arterioles, rather than from common risk factors, and atrial fibrillation and carotid stenosis seem to account for a maximum of 10% to 15% of lacunar strokes. 56 In line with the latter, artheromas and intramural thrombi are rare in lacunar stroke. 55 The typical small arteriolar changes directly related to lacunar lesions include failure of the vascular endothelium with consecutive extravasation of blood components into the vessel wall, fibrinoid wall necrosis with intramural deposition of fibrinoid material, and intimal thickening and hyalinization, by guest on October 15, 2017 http://stroke.ahajournals.org/ Downloaded from all leading to vascular dilation and occlusion, microaneurysms, and often microhemorrhages. 55 Microhemorrhages are a possible risk factor for intracerebral hemorrhage and might increase the risk of hemorrhage, complicating antithrombotic drug treatment compared with their use in cortical ischemic stroke. Similar to the SPS3 trial, >50% of patients in the PRoFESS trial 50 as well as in the MATCH trial 35 had lacunar strokes. Noteworthy, the PRoFESS trial 50 suggests that clopidogrel alone is as effective as aspirin plus dipyridamole, with less intracranial hemorrhage, for clopidogrel monotherapy in a cohort of patients with previous ischemic stroke. Therefore, it might be that patients benefit from DAPT especially in nonlacunar ischemic strokes, predominantly caused by a thromboembolic occlusion of cerebral arteries, when the therapy is given early after symptom onset. 25 Bleeding risk seems to increase over time in patients presenting with lacunar stroke. 21 DAPT with aspirin and novel ADP receptor blockers, such as ticagrelor and prasugrel, did not further reduce the risk of stroke as compared with DAPT with aspirin and clopidogrel. Both drugs showed superiority in the composite end point of 12-month risk of overall death, nonfatal myocardial infarction, or nonfatal stroke (odds ratio, 0.83; 95% CI, 0.77-0.89; P<0.001) 57 in patients with acute coronary syndrome, but our meta-analysis did not show any benefit regarding cerebrovascular events of either drug when combined with aspirin compared with clopidogrel and aspirin. Noteworthy, the use of ticagrelor was associated with a trend toward a higher risk of intracerebral bleeding in the PLATO (ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes) trial. 13 Nevertheless, the data about ticagrelor come from 1 large PLATO trial, 13 which showed fundamental discrepancies in mortality rates 58 and a higher number of patients lost to follow-up. A subgroup analysis of TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With PrasugrelThrombolysis in Myocardial Infarction 38) including patients with previous ischemic stroke or TIA demonstrated more overall bleeding complications and more cerebrovascular events in those with a history of previous stroke when treated with prasugrel. 59 These findings suggest that more effective platelet inhibition, as provided by aspirin plus ticagrelor or prasugrel, yielded no additional protection against recurrent cerebrovascular events but might increase bleeding risk.
This meta-analysis included primarily patients with cardiovascular (not cerebrovascular) disease. The comparison of antiplatelet therapies in patients with TIA/stroke was performed only in few trials. Nevertheless, because DAPT is effective and safe in patients with coronary artery disease, our meta-analysis also confirms that stroke patients also experience a reduction in stroke with DAPT. A fundamental question that remains is what is the optimal time point to start antiplatelet treatment and for how long. Concordantly, the choice of antiplatelet agents for secondary stroke prevention requires further investigation. From indirect comparisons, it seems that the magnitude of RRR of dipyridamole plus aspirin, 49 compared with aspirin, is similar to that achieved by clopidogrel plus aspirin, compared with aspirin (from our meta-analysis). Because cilostazol might be a promising drug for stroke prevention, a trial addressing DAPT with aspirin plus clopidogrel versus cilostazol alone would gain important information. Nevertheless, because there is no direct comparison between these combinations, this consideration is only hypothesis-generating.
Limitations
Most of the data were generated from cardiovascular trials, which have not been designed to evaluate the impact of treatment on the primary end point of stroke. End point classification is driven by a rough scale (stroke: yes/no) and does not discriminate detriment from the event. The median follow-up period for ticagrelor and prasugrel trials was shorter compared with trials comparing DAPT with aspirin and clopidogrel (5.6 versus 9 months). Moreover, information about severity of the end point, such as the stroke severity scale and resulting physical inability, was missing. A further limitation is that studies included in the meta-analyses were characterized by clinical heterogeneity. We included trials that looked at short treatment for acute coronary syndrome, established cardiovascular disease, heart failure, and primary prevention (part of Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization Management and Avoidance [CHARISMA]) 29 with and without baseline cerebrovascular disease. The meta-analysis used studies with disparate populations (eg, secondary prevention after acute coronary syndrome versus secondary prevention after stroke/TIA). Although this may add to generalizability, it could also add to heterogeneity. To acknowledge this heterogeneity, we calculated RR using random-effect estimates, which confirmed the results obtained by fixed-effect estimates (Table II in the online-only Data Supplement). A possible shortcoming of this meta-analysis is that, for some studies, only a combined end point for overall stroke, including ischemic stroke, TIA, or intracranial hemorrhage, was available. Because these conditions have different prognoses, some may object to conflating TIA with stroke. On the other side, according to the AHA guidelines, 5 the distinction between TIA and ischemic stroke has become less important in recent years because many of the preventive approaches are applicable to both groups. They share similar pathogenetic mechanisms. With widespread use of modern brain imaging, most patients with symptoms lasting 24 hours have been found to have an infarction. TIAs are an important determinant of stroke, with 90-day risk of stroke reported as high as 10.5% and the greatest stroke risk apparent in the first week. Therefore, diagnostic workup and therapeutic strategies are similar for stroke and TIA (which is increasingly called minor stroke). The inclusion of Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) 26 trial into the meta-analysis might represent another limitation because the WATCH trial involved a different population (heart failure). Nevertheless, because >70% of patients in the WATCH trial had heart failure based on an ischemic cause, we decided to include this study in our analyses. Moreover, in the sensitivity analysis, the exclusion of WATCH data showed no impact on the results.
Conclusions
This systematic review and meta-analysis indicates that DAPT with clopidogrel plus aspirin as compared with aspirin monotherapy reduces the risk of total and ischemic stroke in the 
